Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach.
During the 10 years 1978 to 1987, 33 patients were hospitalized because of moderate and severe ovarian hyperstimulation syndrome (OHSS) in 39 treatment cycles. Twenty-five treatment cycles ended in moderate OHSS (group A), 7 had severe OHSS without a significant amount of ascites (group B1), and 7 had severe OHSS with ascites (group B2). Groups A and B1 received intravascular volume expander, electrolytes replacement, and indomethacin up to 300 mg/day. The patients in group B2 had significant clinical and biochemical improvement after abdominal paracentesis. Urinary output and creatinine clearance improved significantly, and a decrease in hematocrit, blood osmolarity, and weight reduction were achieved. A strategy for treatment of OHSS based on consecutive ultrasonographic examination, clinical and biochemical evaluation, and abdominal paracentesis in severe OHSS with clinically significant ascites is suggested.
Borenstein
R
R
Kaplan Hospital, Rehovot, Israel.
Elhalah
U
U
Lunenfeld
B
B
Schwartz
Z S
ZS
D000030:Abortion, Missed; D000328:Adult; D001201:Ascites / Q000209:etiology; D004322:Drainage; D004573:Electrolytes / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D010049:Ovarian Diseases / Q000150:complications / Q000209:etiology* / Q000628:therapy; D010062:Ovulation Induction / Q000009:adverse effects*; D010537:Peritoneum / Q000601:surgery; D010952:Plasma Substitutes / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D013577:Syndrome
D004573:Electrolytes; D010952:Plasma Substitutes; D007213:Indomethacin